GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH · global health economics and . outcomes research....

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCHFELLOWSHIP PROGRAMUNIV OF WASHINGTON2018-2020

GHEOR Fellowship Program 2018-2020

PRODUCT VALUE PROPOSITION…outcomes research strategy based on product value, stakeholder needs & insights

VALUE COMMUNICATION …about evidence informing the value proposition to stakeholders

…informs health care decision making

EVIDENCE GENERATION AND TOOL DEVELOPMENT…through clinical and health economics & outcomes research (HEOR) data

Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new

industry model - Growth Pharma. Our company is focused on developing, manufacturing and commercializing branded

pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands

and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology,

women’s health, urology, and anti-infective therapeutic categories. We are an industry leader in research and development,

with one of the broadest innovative development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline

programs in development. With commercial operations in approximately 100 countries, our company is committed to working

with physicians, healthcare providers and patients to deliver innovative and meaningful treatments to help people around the

world live longer, healthier lives. Learn more at www.Allergan.com.

ABOUT OUR COMPANY

OUR WORLD-CLASS MANUFACTURING AND R&D NETWORK

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH (GHEOR)

1

2

3

The University of Washington is a world-class leader in health sciences education and has been consistently listed in

US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly

noted for its strong research programs and since 1974 has received more federal funds for research and training

than any other public university in the United States. It fosters a highly collegial atmosphere between departments

and academic units, creating a particularly attractive environment for such partnerships between the public and

private sectors.

The Pharmaceutical Outcomes Research and Policy Program (PORPP) is housed within the University of Washington

School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1)

provide advanced research training for graduate students, post-doctoral fellows and clinicians (PharmDs, MDs); (2)

conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health

technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with

the goal of improving patient care.

PORPP faculty participating in the fellowship have been chosen both for their dedication to teaching and their

excellence in research. Each is trained either as a health economist or health services researcher and all have an

extensive history of effective economic evaluations and pharmacoepidemiologic research.

ABOUT OUR SCHOOL

GHEOR Fellowship Program 2018-20201 2GHEOR Fellowship Program 2018-2020

USAFall River, MA

Cincinnati, OH

Northern, CA (Biologics)

Irvine, CA (Biologics)

Waco, TX

Jersey City, NJ

Rockaway, NJ

Bridgewater, NJ

Irvine, CA COSTA RICAHeredia, San Jose

BRAZILGuarulhos

IRELANDWestport

Clonshaugh, Dublin

Westport

BELGIUMLiege

GERMANYWeiterstadt

FRANCEPringy

Pringy

MANUFACTURING

CHINABeijing

Shanghai

JAPANTokyo

UKLiverpool

Marlow

R&D

SINGAPORESingapore

GHEOR Fellowship Program 2018-2020 GHEOR Fellowship Program 2018-2020

UNIVERSITY OF WASHINGTON

Beth Devine, PharmD, MBA, PhD, FASHP

Associate Professor

Pharmaceutical Outcomes Research & Policy Program

1959 NE Pacific Avenue, H-375D

Box 357630

Seattle, WA 98195-7630

E-Mail: [email protected]

THE FELLOWSHIP PROGRAM Allergan and the University of Washington are pleased to offer two, 2-year GHEOR Fellowship positions for the academic

year 2018-2020. Fellows will spend their first year at the University of Washington (Seattle, WA), and the second year at

Allergan (Irvine, CA). The objective of the first year is to educate fellows on the principles and methods used in health

economics and outcomes research. During the second year, fellows are provided with opportunities to gain practical

knowledge and experience with the use of clinical, economic, and humanistic data by supporting the development and

commercialization of pharmaceutical products. This will be accomplished by participating in work activities undertaken

by the GHEOR team.

Compensation includes a competitive stipend, basic medical insurance, conference attendance, relocation from

Seattle to Irvine, and holiday/vacation time. A Master’s (MS) Degree is awarded upon completion of all course

requirements and thesis project.

ALLERGAN PLC

Patrick Gillard, PharmD, MS

Director, GHEOR

2525 Dupont Drive

Irvine, CA 92612


Phone: (714) 246-2354

FELLOWSHIP DIRECTORS

The Allergan/University of Washington GHEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain proficiency in health outcomes strategy and research as conducted

in both academic and pharmaceutical industry settings.

FIRST YEAR OBJECTIVESThe objective of the first year is to provide the fellow with the research tools necessary for economic evaluation and

policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy,

and taught methods of economic assessment, health services research, epidemiology, clinical research design, and

biostatistical analyses.

The fellow will be assigned a MS thesis project which is selected based on input from both Allergan as well as the

University of Washington mentors. Fellows are highly encouraged to complete their MS project during their first year.

Additionally, fellows will also engage in ongoing projects with Allergan throughout their first year, applying skills from

previous pharmacy training as well as integrating new techniques developed from University of Washington courses.

Applying learning to solve real-world problems is a constant focus of the fellowship.

The fellow’s actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine,

but will consist of courses in biostatistics, epidemiology, economic evaluations and outcomes research, and health

and pharmaceutical policy.

AFTER COMPLETION OF THE FIRST-YEAR, THE FELLOW WILL HAVE A CLEAR UNDERSTANDING OF:• General principles of economics and in particular how economics influences the use, cost, and availability

of pharmaceuticals.

• The complex structure of drug policy and how it determines relationships between consumers, health care providers,

insurers, payers, and government agencies.

• The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs),

economic modeling, retrospective database studies, and observational studies.

• Formulary development, maintenance and evaluation in institutional, managed care, and state-level

government programs.

1ST YEAR

FELLOWSHIP STRUCTURE

3 4

ABOUT OUR FELLOWSHIP


SECOND YEAR OBJECTIVESThe second year of training will be at Allergan in Irvine, CA with the GHEOR department. This part of the program

is designed to allow the fellow to learn about the role of economic evaluations and outcomes research in the drug

development and commercialization process within the industry setting. The research may be on an existing or

experimental product, for a disease state that is of interest to Allergan.

In addition to completing individual research project(s), fellows will participate in ongoing economic evaluations,

outcomes research, and other projects in collaboration with the GHEOR team. These experiences will provide

the fellow with opportunities to interact with team members in other

departments at Allergan to learn how economic analyses and outcomes

research are used throughout the pharmaceutical industry. Fellows will

see firsthand how outcomes research is utilized to demonstrate the

place of Allergan products in treatment pathways and its value.

UNIVERSITY OF WASHINGTON PROGRAM FACULTY

• Anirban Basu, PhD Professor and Stergachis Family Endowed

Director of PORPP

• Denise Boudreau, PhD Affiliate Professor

• Beth Devine, PharmD, MBA, PhD, FASHP

Associate Professor, Director of

Graduate Programs

• Josh Carlson, MPH, PhD Associate Professor

• Louis P. Garrison, Jr., PhD Professor Emeritus

• Ryan Hansen, PhD, PharmD Assistant Professor

• Thomas K. Hazlet, PharmD, Dr. PH Associate Professor

• Scott D. Ramsey, MD, PhD Professor

• Sean D. Sullivan, PhD Professor and Dean of

School of Pharmacy

• David L. Veenstra, PharmD, PhD Professor and Associate Director of PORPP

Jonathan W. Kowalski, PharmD, MS

Vice President, US HOV

Sepideh Varon, PhDAssociate Vice President, GHEOR

David Macarios, MBA, MSc

Vice President, GEV

Hema Viswanathan, BPharm, PhD

Director, GHEOR

Amy Tung, PharmD, MS Manager, GHEOR

Patrick Gillard, PharmD, MSDirector, GHEOR

Joanna Campbell, PhDDirector, GHEOR

ALLERGAN FELLOWSHIP MENTORS

Vaishali Patel, PharmD, MS

Executive Director, GHEOR

• Joseph Babigumira, MBChB, MS, PhD

Adjunct Associate Professor

• Aasthaa Bansal, PhD Assistant Professor

• Caroline Bennette, MPH, PhD Affiliate Assistant Professor

• Andy Stergachis, BPharm, PhD Professor and Associate Dean for Research,

Graduate Programs and New Initiatives

2ND YEAR

5 6

Anand Shewale, MS, PhD

Manager, GHEOR

Sarah Baradaran, PharmD, MSManager, GHEOR

Vanessa Shih, PharmD, MSManager, GHEOR

Katelyn Keyloun, PharmD, MSManager, GHEOR


CHIEMEKA IKE, PHARMD, MPHChiemeka received her PharmD degree from the University of Houston College of Pharmacy in 2017. Her

interest in the pharmaceutical industry propelled her to start an Industry Pharmacists Organization (IPhO)

chapter at the University of Houston to create awareness and spark interest among pharmacy students in

careers within the pharmaceutical industry. HEOR sparked her interest particularly because she sought to

combine her PharmD and epidemiology background in a pharmaceutical industry career focused on health

outcomes. Chiemeka completed clinical clerkships in managed care, cardiology, and at the U.S. Food and Drug

Administration (FDA) Department of Pediatric Clinical Pharmacology. Prior to pharmacy school, she worked

in clinical guideline development at the American Society for Radiation Oncology (ASTRO) for over two years

where she was responsible for managing systematic review projects in various oncology disease states. In

addition, she obtained a Master of Public Health (MPH) degree in Epidemiology at the George Washington

Milken Institute School of Public Health. Her MPH coursework provided her with a strong epidemiology

background.

Chiemeka is excited to build on her previous epidemiology coursework at the University of Washington.

Her research interests include infectious disease and oncology. She looks forward to applying her skills and

knowledge to her thesis project and other research projects and looks forward to working with the PORPP

faculty and Allergan team. For her thesis, Chiemeka will be using Adelphi survey data to determine treatment

patterns, switching, and cycling of acute medications for migraine.

SARA HIGA, PHARMD, MSSara received her PharmD from the University of Maryland Baltimore (UMB) and her BS and MS degrees

from Georgetown University. Prior to matriculating at pharmacy school, Sara was exposed to comparative

effectiveness research and conducted a literature review at the National Cancer Institute. At UMB, she worked

on various projects ranging from qualitative case studies to retrospective claims database analyses. Her

involvement in the Pharmaceutical Health Services Research Department at UMB was instrumental in fostering

her passion and experience in health economics and outcomes research (HEOR). She developed her skills in

observational research through clerkships in managed care and research, consulting work with Avalere Health,

and completing research methods courses at the PhD level.

Sara is excited to work with the PORPP and Allergan teams to expand her knowledge and skills in HEOR. For

her thesis, she will use MarketScan data to investigate treatment patterns and adherence to pharmacologic

therapies in psoriasis.

MICHAEL SERBIN, PHARMD, MSMichael received a BS in biomedical engineering from USC in 2011 and a PharmD from the University of

Washington School of Pharmacy in 2016. During his first fellowship year Michael conducted an analysis utilizing

the Medical Expenditure Panel Survey (MEPS) database to estimate healthcare resource use, expenditures, and

quality of life differences in glaucoma patients with vs. without select physical and mental comorbidities for his

thesis. Michael worked under the guidance of Professors Beth Devine and Anirban Basu and Allergan GHEOR Eye

Care Director Joanna Campbell.

In his second fellowship year, Michael continued to work in the eye care therapeutic area with projects in

glaucoma and presbyopia at Allergan. He is refining his thesis paper into a manuscript for submission this year, as

well as working on several projects with vendors supporting a number of Allergan products. Michael is enjoying

the Southern California sun and is excited to continue to utilize his outcomes research, economic evaluations, and

statistics skills he developed at UW throughout the second year of his fellowship.

ABSTRACTS FROM FELLOWSHIP: 1. Serbin M, Devine B. Assessing the Societal Burden of Glaucoma Patients Not Suitable for Topical Medication

Therapy. ISPOR 22nd Annual International Meeting, May 2017, Boston MA. (Poster)

2. Serbin M, Devine B. Estimating the Economic Impact of Open-Angle Glaucoma Therapy Options: A

Systematic Review. UW Corporate Advisory Board Meeting, September 2016, Seattle, WA. (Poster)

MANUSCRIPTS FROM FELLOWSHIP:

1. Serbin M, Devine B, Campbell J, Basu A. Assessing the Societal Burden of Glaucoma Patients With vs.

Without Physical or Mental Comorbidities. (In Progress)

SHEILA SHAPOURI, PHARMD, MSSheila joined the University of Washington/Allergan fellowship in 2016 after receiving her PharmD from the

University of Washington and BA from the University of Texas at Austin. During the first year of her fellowship

she completed her thesis titled “Predicting Hospitalizations and Returns to the Emergency Department 30-

Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure

Infections (ABSSSI)” under the mentorship of Professors Beth Devine and Aasthaa Bansal.

During the second year of her fellowship, Sheila has worked in the women’s health therapeutic area. She

is conducting a claims analysis and systematic literature review to support reimbursement and access to a

women’s health product. Additionally, she is working to submit her thesis as a manuscript for publication to

improve the quality of care provided for patients with ABSSSIs. Sheila is looking forward to continuing her

research and applying her training in health economics and outcomes research on site at Allergan during the

second year of the fellowship.

ABSTRACTS FROM FELLOWSHIP:1. Shapouri S, Devine EB. Cost-Utility Analysis of Outpatient Dalbavancin for Acute Bacterial Skin and Skin

Structure Infections (ABSSSI) versus Inpatient Vancomycin Followed by Oral Linezolid. ISPOR 22nd Annual

International Meeting, May 2017, Boston, MA. (Poster)

2. Shapouri S, Keyloun KR, Gillard PJ, Devine EB. Prediction Model for 30-Day Hospital Readmissions or

Emergency Department Revisits Among Patients with Acute Bacterial Skin and Skin Structure Infections

(ABSSSI): A Literature Review. UW Corporate Advisory Board Meeting, September 2016, Seattle, WA. (Poster)

MANUSCRIPTS FROM FELLOWSHIP:1. Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations and

Returns to the Emergency Department 30-Days Post Emergency Department Discharge Among Patients

with Acute Bacterial Skin and Skin Structure Infections. (In Progress)

2ND YEAR FELLOWS

1ST YEAR FELLOWS

CURRENT FELLOWS

7 8


Manager, Global Health Economics and Outcomes Research

Allergan plc, Irvine, CA

MANUSCRIPTS FROM FELLOWSHIP1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and Informal Caregiving

Requirements in Older Americans. (In Progress)

Pharmacy Quality, Utilization, and Clinical Programs Coordinator Kaiser Permanente of Washington

Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP 1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by Disease Severity: A

Retrospective Claims Database Analysis. (In Progress)



MANUSCRIPTS FROM FELLOWSHIP 1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant Therapeutic Class: A

Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 May;31(5):421-432.2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarcyzy-Hornoch P, Devine EB. Characterizing pharmacogenomic-guided

medication use with a clinical data repository. Clin Pharmacol Ther. 2017 Aug;102(2):340-348.3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for

Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science. 2017 Jul; eCollection.

PAST FELLOWS

KATELYN KEYLOUN

PharmD, MS2014-2016

VANESSA SHIH

PharmD, MS2014-2016

TRACY YEPPharmD, MS

2013-2015

Health Economist

Genentech, San Francisco, CA

MANUSCRIPTS FROM FELLOWSHIP1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM.Assessing patterns of use of cardio-protective polypill component medicines in

Australian women. Drugs Aging (2013)30:193-2032. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among Commercially

Insured Non-Elderly Patients With Diabetic Macular Edema. Ophthalmic surgery, lasers & imaging retina. 2015 Jul-Aug;46(7):744-513. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially Insured Working

Age Population Opthalmic Surg Lasers Imaging Retina. 2015 Jul-Aug;46(7):744-51

CHRIS WALLICK

PharmD, MS2012-2014

Research Scientist Evidera, Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary

Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. BMC Urology, 2009; 9(18)

Associate Professor, UCSD Skaggs School of PharmacySan Diego, CA

MANUSCRIPTS FROM FELLOWSHIP1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge

Incontinence Refractory Oral Antimuscarinics. BMC Urology, 2009 Nov;20;9(18).2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory

Patients with Overactive Bladder. Urology, 2010 Oct;76(4):835-40.3. Sand P, Rovner E, Dmochoswki R, Watanabe JH, Oefelein MG. Once-daily Trospium Chloride 60 mg Extended Release is Safe and Effective in

Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. Drugs Aging, 2011 Feb;1;28(2):151-604. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res

Opin, 2011 May, 27(5):1041-8.

Director, Global Health Economics and Outcomes Research


MANUSCRIPTS FROM FELLOWSHIP1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease- Specific Measures to Health-State Utility Values in Individuals

with Migraine. Value in Health 2012;15(3):485-94.2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburgh AM, Elovic EP. Relationship Between Disability Due to Upper-Limb

Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden, PM&R 2012;4(1):4-10.

Manager, JAPAC Regional Health Economics, Amgen

Thousand Oaks, CA

MANUSCRIPTS FROM FELLOWSHIP1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-Severe Psoriasis:

A Bayesian Network Meta-Analysis. Arch Dermatol. 2012 Dec;148(12):1403-102. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients’ experience and outcomes after laparoscopic adjustable gastric

banding in Washington State. Surg Obes Relat Dis. 2013 Sep-Oct;9(5):701-53. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric banding: a

nonlinear approach. Value in Health. 2013 Jul;16(5):823-9

Consultant, Health Economics and Outcomes Research

Seattle, WA

MANUSCRIPTS FROM FELLOWSHIP1. JC Sanderson, EB Devine, RB Lipton, LM Bloudek, SF Varon, AM Blumenfeld, PJ Goadsby, DC Buse, SD Sullivan. Headache-related health

resource utilization in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1309-172. Messali A, Sanderson JC, Blumenfeld AM. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based

Survey. Headache. 2016 Feb;56(2):306-22

JONATHAN H. WATANABE

PharmD, MS, PhD2007-2009

Associate Director Abbvie, Chicago, IL

MANUSCRIPTS FROM FELLOWSHIP1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with

chronic migraine. Cephalalgia. 2015 May;35(6):478-88.2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving

medication safety in ambulatory care. Value Health. 2014 Jun;17(4):340-9

ZSOLT HEPPPharmD, MS

2012-2014

JOANNA SANDERSON

PharmD, MS2011-2013

VINCENT W. LIN

PharmD, MS2010-2012

PATRICK GILLARD

PharmD, MS2009-2010

KATHARINE S. GRIES

PharmD, MS, PHD2008-2010

9 10



MANUSCRIPTS FROM FELLOWSHIP 1. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial

Cystitis: A Retrospective Claims Analysis. Journal of managed care & specialty pharmacy. 2017; 23(4):474-482. 2. Dmochowski R, Brucker B, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D. Economic Burden of Illness in Adult Patients with

Nocturia. (In Progress)

AMY TUNG

PharmD, MS2015-2017



MANUSCRIPTS FROM FELLOWSHIP 1. Baradaran S, Black D, Keyloun K, Hansen R, Gillard P, Devine E. The Impact of Acute Kidney Injury on the Risk of Mortality and Healthcare

Utilization among Patients Treated with Polymyxins for Severe Gram-Negative Infections. (In Progress)2. Kagan R, Martin A, Sarri G, Guo Y, Baradaran S, Harrington A. The Burden of Illness Associated with Symptomatic Vulvovaginal Atrophy

(VVA): A Systematic Review. (In Progress)3 Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for

Pharmacogenomic Biomarker-Guided Medication Use. AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science. 2017; 2017:30-39.

SARAH BARADARAN

PharmD, MS2015-2017

NYSE:AGN | www.Allergan.com

© 2017 Allergan. ® Marks owned by Allergan. All rights reserved

APPLICATION INFORMATIONInterested students must apply to both the University of Washington Graduate

School, as well as the Pharmaceutical Outcomes Research & Policy Program.

The online application process can be found at:

http://sop.washington.edu/department-of-pharmacy/pharmaceutical-

outcomes-research-policy-program-porpp/fellowship-opportunities/

CONTACT INFORMATIONIf you have any questions, please contact:

UNIVERSITY OF WASHINGTON

Michelle Hughes

Program Operations Specialist

Box 357630

University of Washington

Seattle, WA 98195-7630


Phone: (206) 616-1383

Fax: (206) 543-3835

DEADLINE The application deadline is

December 8, 2017

and the start date of the

Fellowship is July 1, 2018

ALLERGAN PLC

Patrick Gillard, PharmD, MS

Director, GHEOR

2525 Dupont Drive

Irvine, CA 92612


Phone: (714) 246-2354

Applicants for this fellowship must have a degree in pharmacy and have some

research experience (preference will be given to those with a high academic

standing). Excellent written and verbal communication skills are also essential.

Applicants will be required to submit their curriculum vitae, a letter

describing their career goals, and three letters of recommendation.

Selection of fellows will be made by a steering committee

composed of the University of Washington faculty

members and representatives from Allergan.

APPLICATION ELIGIBILITY

Programs Offered

University

University Location

Allergan Location

Program Length

Eligibility

UNIVERSITY OF WASHINGTONPharmaceutical Outcomes Research and Policy Program

Seattle, WA

Irvine, CA

2 years

Degree in Pharmacy

Global Health Economics and Outcomes Research

A L L E R G A N F E L LO W S H I P P R O G R A M S

GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH · global health economics and . outcomes research....

Documents

Transcript of GLOBAL HEALTH ECONOMICS AND OUTCOMES RESEARCH · global health economics and . outcomes research....